[BOOK][B] Handbuch Alternative Investments

M Busack, DG Kaiser - 2006 - alternative-investments.de
… Deswegen wünsche ich den Herausgebern – Michael Busack, der auch schon mit dem
Absolut|report seit Jahren das Thema begleitet und Dieter Kaiser, der mit zwei anderen Büchern …

The GITEWS ocean bottom sensor packages

O Boebel, M Busack, ER Flueh… - … Hazards and Earth …, 2010 - nhess.copernicus.org
… The record was taken in 2007 during tests in the Bergen Fjord across at least 500m of
horizontal transmission distance with the transmitter at 20 m and the receiver at 10 m depth. The x-…

Breathing motion compensation for robot assisted laser osteotomy

M Busack, G Morel, D Bellot - 2010 IEEE International …, 2010 - ieeexplore.ieee.org
m to the target’s frame at instant k − m + 1, computed thanks to the records of χta(k − m) and
χta(k − m … Thus, we have m = 160. The parameters of the controller are λv = λω = 1.5 and β = …

Do alternative UCITS deliver what they promise? A comparison of alternative UCITS and hedge funds

M Busack, W Drobetz, J Tille - Applied financial economics, 2014 - Taylor & Francis
We study the performance of alternative UCITS funds and account for potential survivorship
biases in our sample in the best possible manner. Alternative UCITS funds offer similar raw …

Impact of lockdown during the COVID-19 pandemic on health status in patients with cystic fibrosis: a mono-centre observational study

S Thee, LM Busack, MA Mall, M Stahl - ERJ open research, 2022 - Eur Respiratory Soc
Patients with cystic fibrosis (CF) suffer from impaired mucociliary clearance making them more
susceptible to a spectrum of inhaled pathogens including bacteria, fungi and viruses [1, 2]…

Multiple-breath washout to detect lung disease in patients with inborn errors of immunity

LM Busack, S Thee, Y Liu, C Allomba… - ERJ Open …, 2024 - Eur Respiratory Soc
Background Pulmonary manifestations are the major cause of morbidity and mortality in
patients with inborn errors of immunity (IEI). New and more sensitive diagnostic methods can …

[HTML][HTML] Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis

CO Pioch, N Ziegahn, C Allomba, LM Busack… - Journal of Cystic …, 2024 - Elsevier
Background In health, nitric oxide (NO) shows high concentrations in the upper airways,
while nasal NO (nNO) is significantly lower in patients with sinonasal inflammation, such as …

Can investors benefit from the performance of alternative UCITS funds?

M Busack, W Drobetz, J Tille - Financial Markets and Portfolio …, 2017 - Springer
… alternative UCITS funds that was collected by Busack et al. (2014)… We extend Busack et al.’s
(2014) sample by adding funds … bias issues prior to database inception, Busack et al. (2014) …

3D Simulation of the Filtration and Dust Retention Process of a Fuel Filter

…, J Hierro, JL Hernández, M Busack… - Chemical …, 2015 - Wiley Online Library
A model for the description of the dust retention process inside a filter was developed and
successfully applied to a detailed 3D numerical simulation of a Bosch automotive diesel filter. …

P042 Nasal nitric oxide increases in patients with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor

…, SY Graeber, C Allomba, LM Busack… - Journal of Cystic …, 2023 - cysticfibrosisjournal.com
Objectives: In health, nitric oxide (NO) can be measured in high concentrations in the upper
respiratory tract. It has been shown that nasal NO (nNO) is significantly lower in patients with …